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Abstract
The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target
for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies. We have previously reported on the discovery
and preclinical characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety
of animal models. Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD),
and safety of PRT062607 in healthy volunteers following single and multiple oral administrations. PRT062607 demonstrated a favorable PK profile and
the ability to completely inhibit SYK activity in multiple whole-blood assays. The PD half-life in the more sensitive assays was approximately 24 hours
and returned to predose levels by 72 hours. Selectivity for SYK was observed at all dose levels tested. Analysis of the PK/PD relationship indicated an
IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcRI-mediated basophil degranulation.
PRT062607 was safe and well tolerated across the entire range of doses.Clinical PK/PD was related to in vivo anti-inflammatory activity of PRT062607
in the rat collagen-induced arthritis model, which predicts that therapeutic concentrations may be safely achieved in humans for the treatment of
autoimmune disease. PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans
following once-daily oral dosing.
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Spleen tyrosine kinase (SYK) is a cytosolic protein
tyrosine kinase that, upon receptor engagement,
binds to diphosphorylated immune tyrosine activation
motif (ITAM), resulting in tyrosine phosphorylation
of multiple downstream substrates that ultimately
regulate the cell’s survival, functional activation,
differentiation, and clonal expansion. In B cells,
signaling through the B-cell antigen receptor (BCR) is
transduced following antigen ligation by its association
with immunoglobulins Igα and Igβ, each bearing an
ITAM, leading to cellular activation, clonal expansion,
and differentiation into Ig-secreting plasma cells.1
In addition to its role in B-cell development and the
generation of antibody-producing plasma cells,2,3 SYK
is also required for BCR-mediated uptake and presen-
tation of antigen onMHC.4 Fc receptors also associate
with ITAM-containing proteins and utilize SYK for
the initiation of Ig-mediated inflammatory responses
by mast cells and basophils (via FcR)5 and for the
promotion of antigen presentation, oxidative burst,
phagocytosis, and cytokine release by eosinophils,
neutrophils, dendritic cells, and macrophages (via
FcγRs).6 FcγR-dependent antigen/antibody immune
complex uptake and presentation by antigen-presenting
cells are also dependent on SYK.7 SYK inhibition
may therefore indirectly suppress T-cell activation.
Several integrins similarly rely on ITAM-mediated
SYK activation,8 which is critical for neutrophil
oxidative burst and leukocyte recruitment to sites of
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inflammation. Hence, SYK inhibition has the potential
to intervene in several autoimmune mechanisms that
act in concert to promote tissue damage and warrants
further exploration as a therapeutic target in both B-cell
malignancies and autoimmune/allergicy disorders.
PRT062607 (also referred to as P505-15) is a
potent and highly selective small-molecule inhibitor
of SYK discovered by Portola Pharmaceuticals Inc
(South San Francisco, California). The specificity
and potency of SYK inhibition by PRT062607 was
previously evaluated in purified kinase assays and
cellular assays as well as in rodent models to determine
its pharmacokinetics (PK) and pharmacodynamics
(PD) and impact on inflammatory disease. In a
specificity screen of 270 kinases, PRT062607 exhibited
greater than 80-fold selectivity over the next most
potently inhibited kinase and did not cross-react with
the structural homologue ZAP70.9 Other published
reports demonstrated the ability of PRT062607 to
selectively and completely suppress BCR- and FcR-
mediated immune functional responses in whole
blood from healthy volunteers and in whole blood
from patients with active rheumatoid arthritis.10 The
antitumor activity of PRT062607 in diffuse large
B-cell lymphoma cell lines and primary CLL was also
demonstrated.11–13
Described herein, a single ascending dose (SAD)
escalation study in healthy volunteers was initiated at
3 mg and escalated to 400 mg, at which complete
inhibition of SYK was achieved in multiple relevant
assays performed in whole blood collected over a
72-hour period following dosing. A multiple ascending
dose (MAD) escalation study was also conducted in
healthy volunteers, who were dosed once daily for
10 consecutive days, starting at 11 mg and escalat-
ing to 110 mg. The aim of the first in-human stud-
ies was to evaluate the safety, tolerability, PK, and
PD of PRT062607 following oral dosing. The PD
variables measured in whole blood of dosed subjects
included both SYK-dependent (BCR-induced pERK
and up-regulation of cell surface CD69 in B cells, and
FcRI-induced up-regulation of basophil cell surface
CD63) and SYK-independent (BCR-induced pSYK
and PMA-induced pERK in B cells, fMLP-induced
up-regulation of basophil cell surface CD63, and
CD3/CD28-induced up-regulation of T-cell surface
CD69) measures of immune cell functional responses.
Complete inhibition of SYK in peripheral whole-blood
assays was achieved at steady state at the 110-mg dose.
No inhibition of SYK-independent immune functional
responses was observed. PK/PD evaluations enabled
dose projections for efficacy in human autoimmune dis-
ease based on exposures required for efficacy in animal
models.
Methods
Clinical Trial Design
Study protocols were approved by the local site IRB.
Written informed consent was obtained from all sub-
jects prior to study participation.
The SAD study was a single-center, blinded, ran-
domized, placebo-controlled, ascending, single-dose
study of an oral PRT062607 suspension or its matching
placebo, administered to healthy subjects. Doses ranged
from 3 to 400 mg. Within the first 2 groups (n = 4
subjects), 1 subject received placebo and 3 received
PRT062607. Within the next groups (n = 8 subjects), 2
subjects received placebo and 6 received PRT062607.At
each dose level, 2 sentinel subjects (1 active, 1 placebo)
were dosed at least 48 hours in advance of the other
subjects in their respective group. There was at least a
1-week observation period after dosing at each of the
dose levels. The primary objectives were to (1) assess
the safety and tolerability of single ascending oral doses
of PRT062607 in healthy subjects, and to (2) assess the
PK and PD properties of single ascending oral doses of
PRT062607.
The MAD study was a single-center, double-blind,
randomized, placebo-controlled, ascending, multiple-
dose study of a solid formulation (11 mg gelatin
capsules) of PRT062607 or its matching placebo, ad-
ministered to healthy subjects every 24 hours for 10
consecutive days. A total of 32 subjects were enrolled,
divided into 4 sequential groups of 8 subjects at each
dose level (6:2 active:placebo). For each subject, the
total duration of the study was up to 17 weeks (4 weeks
predose, 15 days in the clinical study unit, and 9-
11 weeks after the last dose of study drug, until the
final outpatient follow-up visit). The primary objectives
were to (1) assess the safety and tolerability of multiple
ascending oral doses of PRT062607 in healthy subjects
and (2) determine the PK and PD properties of mul-
tiple ascending oral doses of a solid formulation of
PRT062607 at steady state. Regular safety examinations
were conducted throughout both studies.
Sample Collection
PK Collection. In the SAD study, blood samples for
determination of PRT062607 concentrations were col-
lected at predose and 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 48, 72,
96, and 144 hours postdose. Blood sample collection in-
tervals were shorter in the 2 lowest dose groups: up to 24
hours postdose for the 3-mg group and up to 48 hours
postdose for the 10-mg group. Urine was collected prior
to drug administration for analysis of baseline drug
concentration. Batched urine was collected after oral
administration at the following intervals: 0 to 12, 12 to
24, 24 to 48, 48 to 72, and 72 to 96 hours postdose. In
the MAD study, blood samples were collected on day 1
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(first dose) and 10 (steady state) at predose and 0.5, 1, 2,
3, 4, 6, 9, 12, and 24 hours postdose, and additional 48-,
72-, 96-, and 144-hour postdose samples were collected
for day 10. For the 110-mg group, additional 120- and
192-hour postdose samples were collected for day 10.
Peak (2 and/or 4 hours postdose) and trough (predose;
to assess time to steady state) samples were collected
during the course of the study on days 4, 7, 8, and 9.
Urine was collected prior to drug administration for
analysis of baseline drug concentration. Batched urine
was collected after oral administration on days 1 and 10
at 0-24 hours postdose.
PD Collection. In the SAD study PD samples were
collected at predose and 1, 2, 4, 6, 9, 12, 24, 48, and
72 hours postdose for all dose groups. In the MAD
study PD samples were collected on day 1 at predose
and 1, 2, 4, 6, 9, 12, and 24 hours postdose, on day 4
at predose and 2 and 4 hours postdose, and on day 10
at predose and 0, 1, 2, 4, 6, 9, 12, 24, 48, and 72 hours
postdose.
Analytical Methods
A sensitive and specific liquid chromatography-tandem
mass spectrometry (LC-MS/MS) method was de-
veloped and validated by Worldwide Clinical Tri-
als (Austin, Texas) and was used to determine
PRT062607 concentrations in K2EDTA human plasma
and urine. PRT062607 and stable labeled internal stan-
dard were extracted from human plasma and urine
by solid-phase extraction. Urine samples were forti-
fied with 3-[(3-cholamidopropyl) dimethylammonio]-
1-propanesulfonate (CHAPS) prior to extraction in
order to prevent adsorption to polypropylene. The
plasma method was validated for a range of 0.500
to 500 ng/mL, based on the analysis of 0.100 mL
of human plasma. The urine method was validated
for a range of 50.0 to 1000 ng/mL and 10.0 to
1000 ng/mL for the SAD andMAD study, respectively,
based on the analysis of 0.100 mL of human urine.
Chromatographic separations were performed over a
Phenomenex Synergi Polar-RP column (50 × 2.0 mm,
4 μm) (Phenomenex, Torrance, California). MS/MS
analysis was performed using a Sciex API-4000 triple
quadrupole mass spectrometer with a TurboSpray ion
source (Applied Biosystems, Foster City, California).
The peak area of the m/z 394→360 PRT062607 prod-
uct ion was measured against the peak area of the
m/z 397→363 internal standard product ion. For the
plasma assay, intra-assay precision (%CV) and accu-
racy (% bias) were within 0.8% to 4.5% and –10.1%
to 7.8%, respectively, and interassay precision (%CV)
and accuracy (% bias) were 2.0% to 3.8% and −7.3%
to 6.0%, respectively. For the urine assay, intra-assay
precision and accuracy were within 1.4% to 10.6% and
−12.6% to 0.0%, respectively, and interassay precision
and accuracy were 2.5% to 7.8% and−11.0% to−3.7%,
respectively.
PK Analysis
SAD Study. Pharmacokinetic calculations based on
PRT062607 plasma concentrations were performed
by Quintiles Inc (Durham, North Carolina) using
noncompartmental analysis and appropriate models
(Model 200 extravascular administration) in WinNon-
lin Professional Version 5.2 (Pharsight Corporation,
Mountain View, California). Individual plasma
concentration data from each subject and the exact
time points for blood sampling were used throughout
the analysis. Pharmacokinetic parameters calculated
from plasma PRT062607 concentrations included, but
were not limited to, maximum plasma concentration
(Cmax), time of maximum concentration (tmax), area
under the plasma concentration-time curve from time
0 to time of last measurable concentration (AUClast),
area under the plasma concentration-time curve from
time 0 extrapolated to infinity (AUC0-), apparent
terminal rate constant (λz), and apparent terminal half-
life (t1/2). Dose-normalized values for Cmax and AUClast
were calculated and captured as Cmax/D and AUC/D,
respectively. From urine data, cumulative amount
excreted from time 0 to 96 hours postdose (Ae0-96) and
cumulative fraction of dose excreted unchanged in the
urine from time 0 to 96 hours postdose (fe0-96) were also
determined.
MAD Study. Pharmacokinetic calculations based on
PRT062607 plasma concentrations were performed by
Covance Laboratories (Princeton, New Jersey) using
noncompartmental analysis in WinNonlin Enterprise
Version 5.2 (Pharsight Corporation, Mountain View,
California). Individual plasma concentration data from
each subject and the exact time points for blood sam-
pling were used throughout the analysis. Pharmacoki-
netic parameters calculated from plasma PRT062607
concentrations included, but were not limited to, Cmax,
tmax, AUC0-24, λz, and t1/2. Dose-normalized values for
Cmax and AUC0-24 were calculated and captured as
Cmax/D and AUC/D, respectively. Accumulation ratio
based on Cmax was calculated as Cmax,day 10/Cmax,day 1
and for AUC as AUC0-24,day 10/AUC0-24,day 1. Peak-to-
trough ratio was computed as the ratio of Cmax on
day 10 to the 24-hour concentration postdose on day
10. Fluctuation on day 10 was calculated as (Cmax -
Cmin)/Cavg where Cmin is the minimum concentration
and Cavg is the average concentration. From urine data,
cumulative amount excreted from time 0 to 24 hours
postdose (Ae0-24) and cumulative fraction of dose ex-
creted unchanged in the urine from time 0 to 24 hours
postdose (fe0-24) were also determined. Renal clearance
(CLr) was calculated as the ratio of Ae0-24 to AUC0-24
on day 10.
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Statistical Analysis for PK
Quantitative variables were summarized using descrip-
tive statistics including N, arithmetic mean, standard
deviation (SD), geometric mean, coefficient of varia-
tion (CV in %), median, and minimum and maximum
values.
Reagents
The chemical structure of PRT062607 4-((3-(2H-1,2,
3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclo-
hexyl)amino)pyrimidine-5-carboxamide acetate, also
referred to as P505-15, is published.9
Antibodies obtained fromBDBiosciences (San Jose,
California) include mouse anti–human SYK tyrosine
(Y) 352/ZAP70Y319 phycoerythrin, CD3 allophyco-
cyanin, CD19 allophycocyanin, CD14 alexafluor 488
and allophycocyanin conjugates, CD80 and CD86 phy-
coerythrin, CD69 phycoerythrin, MHCII peridinin-
chlorophyll protein, and CD1a allophycocyanin. The
following reagents were procured from other sources:
ERK threonine (T) 202/Y204 alexafluor 488 (Cell
Signaling Technologies, Danvers, Massachusetts), goat
anti–human IgE and anti–human IgD (Bethyl Labo-
ratories, Montgomery, Texas), CD3/CD28 Dynabeads
(Life Technologies Corporation, Grand Island, New
York), CD14 microbeads and MS columns for mono-
cyte purification from whole blood (Miltenyi Biotech,
Auburn, California), recombinant human IL4 and
GM-CSF (R&D Systems, Minneapolis, Minnesota),
BasoTest and Phagoburst kits for measuring basophil
degranulation and neutrophil oxidative burst, respec-
tively (Orpegen Pharma, Heidelberg, Germany), lym-
phoprep solution for peripheral blood mononuclear
cell isolation (Stem Cell Technologies, Vancouver,
Canada), phosphate buffered saline (PBS), bovine
serum albumin (BSA), phorbol 12-myristate 13-acetate
(PMA), and lipopolysaccharide (LPS) were all ob-
tained from Sigma-Aldrich (St. Louis,Missouri). Sheep
red blood cells were purchased from MP Biomedicals
(Burlingame, California), and sheep red blood cell
opsonizing antibody was obtained from Cell Biolabs,
Inc (San Diego, California).
Human Whole-Blood Assays
Whole blood collected into lithium heparin vacutainer
tubes was used for all assays. Basophil degranulation
was measured using the BasoTest kit as previously
described.9 Blood was stimulated with fMLP (supplied
in the BasoTest kit) as an SYK-independent specificity
control or with anti-IgE to cross-link FcRI leading to
SYK-dependent basophil degranulation. Basophil de-
granulation was measured by up-regulation of surface-
expressed CD63. B-cell activation was measured by
CD69 up-regulation on B cells following stimulation
overnight (16-18 hours) with anti-IgD antibody or
with PMA (80 nM). BCR signaling responses were
measured by intracellular phospho-flow cytometry de-
tecting LYN-mediated SYKY352 phosphorylation as a
specificity control, and ERK Y204 phosphorylation as
an event downstream of SYK. PMAwas used at a final
concentration of 80 nM to induce ERKY204 phospho-
rylation via protein kinase C as a specificity control.
The B-cell assays were also previously described in
detail.9 In the MAD study, T-cell function following
different stimulationswas also assessed. Blood (100μL)
was stimulated overnight with 10 μL CD3/CD28 Dyn-
abeads or with 80 nM PMA. Blood was then stained
with antibodies to detect surface CD3 and CD69. For
each assay, percentage inhibition was calculated by
normalizing to the signaling or functional response
obtained with the predose sample.
Dendritic Cell Activation
An aliquot of 30 mL human whole blood was lay-
ered over 15 mL of lymphoprep density medium and
centrifuged at 400g for 20 minutes to obtain PBMCs.
Recovered cells were washed once in PBS containing
1% BSA and 2 mM EDTA (isolation buffer) and re-
suspended in 360 μL of ice-cold isolation buffer. Then,
40 μL of CD14 microbeads was added to the cells and
incubated 30 minutes on ice. Cells were washed once in
isolation buffer and purified over anMS column per the
manufacturer’s recommendations. Isolated monocytes
were suspended in tissue culture medium and verified
for purity (>95%) by FACS analysis staining with
CD14-specific antibody. Monocytes were then aliquot-
ted into 24-well plates and cultured with 12.5 ng/mL
IL4 and 20 ng/mLGM-CSF for 5 days, after which they
were stained for CD14 (monocyte marker) and CD1a
(immature dendritic cell marker) and assessed for differ-
entiation to immature dendritic cells by flow cytometry.
Immature dendritic cells were then aliquotted 0.5 ×
106 cells per well in a 6-well plate and preincubated
for 1 hour with various concentrations of PRT062607,
then stimulated overnight with 1 μg/mL LPS as an
SYK-independent stimulation control, or with 50 μL
antibody-opsonized sheep red blood cells (opRBC) to
elicit SYK-dependent FcγR-induced cellular activa-
tion. opRBC were prepared by washing 200 μL RBCs
with PBS; they were then suspended in 1 mL PBS
containing 2 μL opsonization solution and incubated
at 37°C for 30 minutes. The RBCs were then washed
twice in PBS and suspended in 1mL PBS. Dendritic cell
activation wasmeasured by flow cytometry the next day
by surface staining for CD80/86 and MHCII.
Neutrophil Oxidative Burst
Heparinized blood, 100 μL, was aliquotted into FACS
tubes and preincubated with various concentrations of
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PRT062607 or vehicle control for 1 hour at 37°C in
a tissue culture incubator prior to stimulation. Cells
were stimulated with 50 μL opRBC as described before
or with 20 μL of anE coli suspension used as an
SYK-independent stimulation control (supplied in the
PhagoBurst kit). Blood was incubated with stimula-
tions (or 50 μL of the supplied washing buffer as a
nonstimulation control) for 10 minutes in a 37°C water
bath. Detection of oxidative burst was performed as
described in the protocols suppliedwith the PhagoBurst
test kit.
Rat Collagen-Induced Arthritis Model and Whole Blood
Phospho-Flow
The rat collagen-induced arthritis (CIA) model was
previously described in detail.9 Briefly, male Sprague-
Dawley rats were immunized with bovine collagen
and randomized into treatment groups on develop-
ment of hind-paw inflammation with clinical scores
of 1 to 2. Whole blood was drawn from immunized
rats with inflammation scores of 1 to 2 into lithium-
heparin tubes, and 100-μL aliquots were preincubated
for 1 hour in a 37°C tissue culture incubator with
various concentrations of PRT062607. Blood was then
stimulated for 5 minutes with biotinylated anti–rat IgD,
followed by the addition of 1 μg streptavidin for an
additional 10 minutes. Whole blood was then fixed
and lysed by the addition of 3 mL prewarmed (37°C)
BD FACS Lyse Buffer (BD Biosciences, San Jose,
California). Cells were washed twice in PBS, and cell
membranes were permeablized in 50% methanol/PBS
(prechilled to−20°C) for 1 hour at 4°C. Cells were then
washed in PBS containing 1% bovine serum albumin
and stained for 1 hour at room temperature with mouse
anti–rat IgM phycoerythrin conjugate and rabbit
anti–human/mouse ERK Y204 Alexafluor 488. B cells
were gated based on IgM-positive staining for evalua-
tion of BCR-induced signaling to ERK.
PD Analysis
The data for PD assays were analyzed using the soft-
ware R together with the drc package.14 The equation
was used to perform robust regression on the dose-
response data, which were transformed to percentage
of inhibition.
f (x) = c + (d − c)
1 + exp (b (log (x) − log (e)))
The parameters c and d are the lower and upper
limits with d fixed to 100% inhibition. The param-
eter e represents the dose with a response halfway
between c and d (ED50), and b the relative slope around
e. The approximate errors were calculated using the
delta method.15 The data were visualized using the
ggplot2 package. Doses required for specific response
Figure 1. Plasma concentration-time profiles following oral adminis-
tration of PRT062607. Plasma concentrations (y-axis, ng/mL) over time
(x-axis, hours) are shown for the SAD (A) and MAD (B) studies. Dose
groups are represented by symbols, as shown.Results for the MAD study
represent steady-state concentrations (day 10).
levels were calculated by inverse regression using the
fitted model. Excel, Prism (GraphPad Software Inc,
San Diego, California), and FlowJo (Ashland, Oregon)
were used to analyze flow cytometry data.
Results
Pharmacokinetics of PRT062607
The PK and PD of PRT062607 were evaluated in 2
consecutive clinical studies following oral administra-
tion in healthy volunteers. In both studies escalation
was terminated when complete target inhibition was
achieved based on a range of SYK-specific PD as-
says. Figure 1 represents the plasma concentration-
time profiles following single doses in the SAD study
and at steady-state (day 10) following 10 consecutive
doses in the MAD study. Mean PK parameters for all
cohorts in the SAD and MAD (at steady state) studies
are summarized in Tables 1 and 2. In the SAD study,
exposure parameters (AUC0-24 and Cmax) increased
with increasing dose of PRT062607 within the entire
dose range of 3 mg to 400 mg with the exception of the
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Table 1. Mean (SD) Plasma and Urine Pharmacokinetic Parameters of PRT062607 from SAD Study
Dose (mg) N Cmax (ng/mL) AUClast (ng·h/mL) Cmax/D (ng/mL)/(mg) AUC/D (ng·h/mL)/(mg) t1/2 (hours) tmaxa (hours) Ae0-96 (mg) fe0-96 (%)
3 3 1.5 (0.4) b 0.5 (0.1) b b 1.0 (0.5, 2.0) NDc NDc
10 3 10.5 (2.6) 150 (60.1) 1.1 (0.3) 15.0 (6.0) 57.1 (9.0) 1.0 (1.0, 1.0) NCd NCd
30 6 42.9 (20.1) 878 (341) 1.4 (0.7) 29.3 (11.4) 56.7 (6.3) 1.0 (0.5, 3.0) 0.4 (0.3) 1.5 (0.9)
100 6 263 (48.1) 5400 (1100) 2.6 (0.5) 52.6 (9.8) 69.8 (30.9) 2.0 (1.0, 3.0) 2.4 (0.5) 2.4 (0.5)
200 6 629 (189) 13,700 (3770) 3.2 (0.9) 68.3 (18.8) 77.2 (31.6) 2.0 (2.0, 3.0) 4.3 (0.8) 2.2 (0.4)
300 6 558 (160) 11,800 (2370) 1.9 (0.5) 39.3 (8.0) 93.8 (46.3) 2.1 (1.0, 3.0) 7.0 (2.0) 2.3 (0.7)
400 6 996 (261) 22,300 (4770) 2.5 (0.7) 55.7 (11.9) 65.1 (13.3) 4.0 (3.0, 4.0) 20.2 (14.3) 5.1 (3.6)
aMedian (Min, Max) presented for tmax.
bValues were not reported due to incomplete concentration-time profile and insufficient detectable concentrations in terminal phase.
cND:Not determined due to urine collection issues.
dNC:Not calculated as all samples were BLQ (< 50 ng/mL).
Table 2. Mean (SD) Plasma and Urine Pharmacokinetic Parameters of PRT062607 from MAD Study (Day 10)
PRT062607 Dose
PK Parameter Units 11 mg 33 mg 66 mg 110 mg
N 6 6 6 6
Cmax ng/mL 32.6 (11.6) 118 (42.7) 317 (164) 557 (200)
AUC0-24 ng·h/mL 507 (206) 1810 (619) 4630 (1847) 8487 (2357)
Cmax/D (ng/mL)/mg 3.0 (1.1) 3.6 (1.3) 4.8 (2.5) 5.1 (1.8)
AUC/D (ng·h/mL)/mg 46.1 (18.7) 54.9 (18.7) 70.1 (28.0) 77.2 (21.4)
t1/2 Hours b b 61.3 (10.2) 75.3 (11.2)
tmaxa Hours 1.5 (0.5, 2.0) 1.5 (1.0, 2.1) 4.0 (2.0, 4.0) 3.0 (3.0, 6.0)
Accumulation Ratio
Cmax 2.9 (2.7) 2.1 (0.7) 3.2 (1.4) 3.3 (2.5)
AUC 5.4 (2.6) 3.2 (1.1) 4.3 (2.1) 5.4 (5.1)
Peak/Trough Ratio 2.0 (0.6) 2.1 (0.2) 2.2 (0.3) 2.3 (0.5)
Fluctuation % 90.7 (43.9) 88.0 (15.9) 98.8 (24.1) 92.8 (30.7)
Ae0-24 mg 0.4 (0.1) 1.3 (0.0) 3.7 (0.6) 6.96 (1.7)
fe0-24 % 3.3 (1.3) 4.0 (0.1) 5.6 (1.0) 6.3 (1.5)
CLr mL/(min·kg) 0.2 (0.1) 0.2 (0.1) 0.2 (0.0) 0.2 (0.1)
aMedian (Min, Max) presented for tmax.
bValues were not reported due to incomplete concentration-time profile and insufficient detectable concentrations in the terminal phase.
200-mg dose, which exhibited slightly higher exposure
than the 300-mg dose. The increase in exposure param-
eters were more than dose proportional from 10 mg to
200 mg. Between the 200-mg and 400-mg doses, the ex-
posure continued to increase in an approximately dose-
proportional manner. Mean Cmax and AUC as they
relate to dose are presented graphically in Supplemental
Figures S1A and B. Mean apparent terminal half-life
(range 57 to 94 hours) as well as median time to peak
plasma concentration (range 1.0 to 4.0 hours) were
similar across the selected dose range and appeared to
be independent of the administered dose. Intersubject
variability (%CV) for exposure parameters (Cmax and
AUClast) were generally low to moderate (<40% for 6
out of 7 dose cohorts). Mean fraction of PRT062607
dose excreted as unchanged drug in urine ranged from
1.47% to 5.07%, indicating that urinary excretion is not
the primary pathway for elimination of PRT062607.
In theMAD study, PRT062607 was readily absorbed
(median tmax between 1.5 to 4.0 hours postdose) and
slowly eliminated. Mean apparent terminal t1/2 values
at dose levels of 66 and 110 mg were 61.3 and 75.3
hours, respectively. Mean Cmax and AUC0-24 values
generally increased in a greater than dose-proportional
manner from 11 to 110 mg. Mean Cmax and AUC
as they relate to dose are presented in Supplemental
Figures S1C and D. Following dose increases of 3-, 6-
and 10-fold, Cmax increased 3.6-, 9.7-, and 17-fold, and
AUC0-24 increased 3.6-, 9.1-, and 17-fold, respectively.
There was approximately a 3- to 5-fold accumulation
of PRT062607 (based on AUC) after once-daily dosing
for 10 days. Comparison of the trough (predose) levels
collected on days 4, 7, 8, 9, and10 of the study (data
not shown) indicated that steady state appeared to have
been achieved by day 7. Mean peak-to-trough ratio on
day 10 ranged from 2.00 to 2.30 across all the dose
cohorts. At steady state, intersubject variability (CV%)
for exposure parameters was generally low to moder-
ate (45% for all dose cohorts). Additional plasma
concentration-time profiles and mean PK parameters
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Figure 2. Oral administration of PRT062607 results in concentration-dependent and selective inhibition of SYK. PRT062607 PK/PD relationships
are shown. (A and B) Data from the SAD (filled circles) and MAD (open circles) studies are overlaid. Percentage inhibition of BCR/SYK-mediated
B-cell activation (A), FcR1/SYK-mediated basophil degranulation (B),BCR/SYK-mediated pERK Y204 (C), and BCR/LYN-mediated pSYK Y352 (D) are
shown on the y-axes, relative to PRT062607 plasma concentration (nM) on the x-axes. The inset box and whisker plot depict the median percentage
inhibition (horizontal black line), the range in which 95% of the data fell (defined by box dimensions), and the 2.5% outliers in either direction (error
bars) observed for each assay in healthy volunteers receiving placebo control. IC50s generated from nonlinear fits of all data combined are shown.
for all cohorts following administration of the first dose
of PRT062607 in the MAD study (day 1) are presented
in Supplemental Figure S2.
Renal excretion was a minor route of elimination for
PRT062607. The mean percentage of unchanged drug
recovered in urine over 24 hours ranged from 3.29%
to 6.32% on day 10. Mean renal clearance observed
on day 10 at the different dose levels appeared to
be dose independent and represented a small frac-
tion of the total apparent oral clearance (data not
shown).
PK/PD Relationship in Healthy Normal Volunteers
Previous publications have shown the specificity of
SYK inhibition on in vitro addition of PRT062607 to
human whole blood and in animal models of various
diseases.9,10 To confirm the PK/PD relationship in
healthy volunteers following oral dosing, we initiated
SAD and MAD studies in which time-matched blood
samples were collected for PK and PD analyses to
determine the PK/PD relationship in humans. Per-
centage inhibition of BCR-mediated B-cell activation
(Figure 2A) and FcR1-mediated basophil degranu-
lation (Figure 2B) were plotted against the plasma
concentration for each sampling time-point. Data from
the SAD (filled circles) and from the MAD (open
circles) are overlaid. The overall IC50 for SYK in the B-
cell activation assay was 324 nM, and in the basophil
degranulation assay it was 205 nM. IC90 for Syk in
the B-cell activation assay was 1.46 μM, and in the
basophil degranulation assay it was 0.71 μM. Table 3
depicts the percentage inhibition of SYK in various
assays extrapolated from the PK/PD plots. The drug
effect on BCR signaling was evaluated only in the SAD
study. The concentration-response curve is shown in
Figure 2C. The assay is more technically challenging
and therefore variable, but as in the activation as-
say, specific inhibition of the signaling pathway was
observed. SYK-mediated pERK Y204 was inhibited
with an IC50 of 660 nM. No concentration-dependent
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Table 3. Inhibitory Concentrationsa
SAD & MAD Merged (All Cohorts)
B-Cell Activation (CD69) Basophil Degranulation (CD63)
95% Confidence 95% Confidence
IC Estimate (nM) Standard Error Lower Upper Estimate (nM) Standard Error Lower Upper
10 72 4 63 80 59 3 53 65
20 125 5 115 135 93 4 86 101
25 152 6 141 164 110 4 103 117
30 181 6 169 194 127 4 119 134
40 245 9 228 262 163 4 155 171
50 324 13 297 350 205 4 196 213
60 427 21 386 469 257 5 248 266
70 578 35 509 647 330 6 319 342
75 687 46 596 778 381 7 367 395
80 836 63 712 961 448 10 429 467
90 1458 146 1172 1744 709 22 665 753
100 2432 299 1845 3019 1082 46 991 1173
aInhibitory concentrations (IC) in BCR-induced B-cell activation and FcR1-induced basophil degranulation assays corresponding to PRT062607 exposure (nM)
were estimated using all PK/PD data from the SAD and MAD cohorts, fit using the software R together with the drc package. Standard error and upper and
lower 95% confidence intervals are shown.
inhibition of LYN-mediated pSYKY392 was observed
(Figure 2D), demonstrating specificity of action on the
BCR signaling pathway.
Figure 3 demonstrates the specificity and reversible
nature of SYK inhibition following a single dose
of PRT062607, consistent with its mechanism of ac-
tion (noncovalent ATP-competitive binding to SYK).
Whole blood isolated from volunteers at baseline and
at several time points postdosing were evaluated in 3
assays. B-cell activation (as measured by up-regulation
of cell surface CD69) was induced by ligating the
BCR (SYK-dependent) or by inducing protein kinase
C using PMA (SYK-independent). Basophil degran-
ulation (as measured by up-regulation of cell sur-
face CD63) was induced by cross-linking the FcR1
(SYK-dependent) or by ligating formyl peptide recep-
tor 1 (fMLP: SYK-independent degranulation). The
BCR signaling pathway was monitored by intracellu-
lar phospho-flow cytometry following BCR ligation.
SYK-mediated pERK Y204 was measured, as was
LYN-mediated pSYK Y352 (as a specificity control).
PMA was additionally used as an SYK-independent
stimulation to monitor PRT062607 effect on protein
kinase C–induced pERK Y204. The data shown in
Figure 3 are for the 200- and 300-mg dose cohorts
combined (SAD study), as the plasma exposure to drug
was not different in the 2 cohorts. BCR-mediated B-
cell activation was inhibited by >75% between 1 and
4 hours and returned to predose levels after 24 hours
following study drug administration. As expected, no
inhibition of PMA-induced B-cell activation was ob-
served (Figure 3A). FcR1-mediated basophil degran-
ulation was >80% suppressed on average between 1
and 6 hours postdose, which was also reversible and
returned to baseline by approximately 48 to 72 hours
after study drug administration. No inhibition of SYK-
independent fMLP-mediated basophil degranulation
was observed (Figure 3B). In the B-signaling assay,
SYK-mediated pERK Y204 was inhibited by approxi-
mately 75% at 2 hours following study drug administra-
tion and returned to baseline by 48 hours. No consistent
inhibition of BCR-mediated pSYK Y352 or PMA-
mediated pERK Y204 was observed (Figure 3C). On
each plot, the average plasma exposure to PRT062607
in time-matched blood samples is shown by the black
tracing.
Similar results were observed in the MAD study.
Only modest inhibition of SYK signaling in the ba-
sophil degranulation assay was observed at the 33-
mg dose. A more robust inhibition of SYK-mediated
signaling was achieved after 10 days of dosing of 66 mg
PRT062607, with data indicating approximately 80%
(or greater) inhibition in the basophil degranulation
assay and approximately 60% inhibition in the B-cell
activation assay. The highest dose tested (110 mg)
resulted in complete inhibition of SYK in the basophil
degranulation assay and a mean of approximately 80%
inhibition on day 10 in the B-cell activation assay.
Because the plasma concentration of PRT062607 di-
minished with time following dosing, the effect on
SYK inhibition in both assays was also diminished,
again revealing the reversible nature of the inhibition.
Further, at all dose levels studied, there was no effect
of PRT062607 plasma concentration on the SYK-
independent stimulations (fMLP and PMA; data not
shown).
Coffey et al 9
Figure 3. Kinetics of SYK inhibition following a single oral dose of PRT062607. The percentage of predose levels of BCR/SYK- (anti-IgD; dark gray
bars) or PMA/PKC- (light gray bars) induced B-cell activation (A), FcR1/SYK- (anti-IgE; dark gray bars) or fMLP- (light gray bars) induced basophil
degranulation (B), and BCR/SYK-mediated pERK Y204 (black bars), BCR/LYN-mediated pSYK Y352 (light gray bars), and PMA/PKC-mediated pERK
Y204 (dark gray bars) (C) are shown on the first (left) y-axis. The average PRT062607 plasma concentration (nM) is presented as a tracing and defined
on the second (right) y-axis. Hours postdose are depicted on the x-axis. Error bars represent the standard error of the mean.
The closest structural homologue to SYK is ZAP70,
responsible for signaling and functional responses
downstream of the T-cell antigen receptor (TCR).16 We
previously reported that PRT062607 does not inhibit
ZAP70 in a purified kinase assay (SYK IC50 = 1
nM, ZAP70 IC50 = 1050 nM).9 To further confirm
this observation, we implemented in the MAD study
measures of T-cell function following CD3/CD28
cross-linking (ZAP70-dependent) or PMA stimulation
(PKC-dependent) to determine if PRT062607 affected
T-cell functional responses following oral dosing. As
shown in Figure 4, no effect on CD3/CD28- (filled
circles) or PMA-induced (open circles) T-cell activation
was observed. These data support the specificity of
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Figure 4. PRT062607 does not inhibit T-cell functional responses following 10 days of consecutive dosing in healthy volunteers. (A) Percentage
inhibition of T-cell activation following CD3/CD28 cross-linking (black-filled circles) or PMA stimulation (gray-filled circles) is shown across the plasma
concentrations achieved (x-axis; nM) at steady state following 10 consecutive once-daily doses from the MAD study. (B) Data from the highest-dose
cohort (110 mg once daily) are presented as percentage of predose baseline (BL) over time, shown in days and hours (h).
action of PRT062607 against SYK and demonstrate
that it does not cross-react with ZAP70 to elicit an
inhibitory T-cell response. Data are also shown in
Figure 4B at the 110-mg dose level over time.
Tolerability
The evaluation of safety included adverse events (AEs),
safety laboratory tests (hematology, serum chemistry,
immune function test panel, urinalysis), vital signs
(sitting), 12-lead ECGs (supine), cardiac monitoring,
and physical examination.
In the SAD study there were no serious adverse
events (SAEs), and no subject was withdrawn as a
result of treatment-emergent adverse events (TEAEs).
A total of 40 AEs were reported, including 1 predose
AE of mild headache. Overall, 39 TEAEswere reported
by 19 subjects; 37 TEAEs were reported by 17/42
(40%) subjects receiving PRT062607, and 2 TEAEs
were reported by 2/12 (17%) subjects receiving placebo.
All of the TEAEs had resolved by the time of the last
subject follow-up. The TEAEs with the highest subject
incidence were headache (6 PRT062607 subjects and
1 placebo subject), dizziness, abdominal pain, nausea,
and diarrhea (3 PRT062607 subjects each) and rhini-
tis (2 PRT062607 subjects). There was no consistent
relationship between increasing dose of PRT062607
and number and incidence of TEAEs. The greatest
subject incidence of events was in the 200-mg and 300-
mg PRT062607 dose groups (both 67%); however, the
highest (400-mg) dose group had a similar subject inci-
dence of TEAEs to placebo (17% for both groups). The
200-mg PRT062607 dose group also had the greatest
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number of reported TEAEs (15), whichwas higher than
any of the other dose groups. Subjects in the 300-mg
PRT062607 dose group reported 7 TEAEs, and those
in the 400-mg dose group reported 3 TEAEs, which was
similar to the number reported by the placebo group
(2 TEAEs). Most (36/39) TEAEs were mild intensity;
3 moderate intensity TEAEs (dizziness, headache, and
musculoskeletal pain) were reported by 3 subjects, all of
whom received PRT062607.
In the MAD study there were no SAEs, and no
subjects were discontinued due to AEs. The AEs re-
ported for all treatments were predominantly mild in
severity. Overall, 71 of 96AEs (74%) reported following
PRT062607 were considered by the investigator to be
related to the study drug. The frequency of AEs was
highest at the 110-mg dose of PRT062607 compared to
the lower doses, and also compared to the placebo treat-
ment, with the frequency for the 11-, 33-, and 66-mg
doses of PRT062607 being similar to that for placebo;
however, the incidence of AEs was similar across the
treatments.Overall, 96AEswere reported by 13 (54.2%)
subjects following administration of PRT062607 com-
pared with 19 AEs reported by 7 (87.5%) subjects
following placebo. The majority (93%) of AEs for the
110-mg dose (55% of AEs in the study) were reported
by 2 subjects, both of whom completed the study and
remained on the study drug. TEAEs reported at the
110-mg dose were all mild in nature and included gas-
trointestinal symptoms (nausea, diarrhea, abdominal
discomfort), hyperhidrosis, fatigue, and loss of appetite.
In neither study were there any consistent trends in
safety laboratory test results, vital signs data or 12-lead
ECG findings following treatment with PRT062607
when compared to placebo.
PRT062607 Inhibits FcR Function in Healthy Normal
Leukocytes
SYK is also critical for FcγR signaling,6,17,18 which
was not measured as part of the clinical trials due to
limitations in accessible blood volume. We therefore
evaluated the ability of PRT062607 to inhibit immune-
complex–driven FcγR-mediated DC activation and
neutrophil oxidative burst using in vitro assays. Imma-
ture dendritic cells were generated from IL4/GMCSF
stimulated peripheral blood monocytes isolated from
healthy donors (Figure 5A) and then stimulated with
antibody-opsonized sheep red blood cells (opRBC) in
the presence or absence of a concentration range of
PRT062607 (Figure 5B). Cellular activation was par-
tially inhibited by an FcγRII-specific antibody (4.3).
PRT062607 inhibited FcγR-mediated DC activation,
as measured by up-regulation of surface CD80/86 and
MHCII on the cell surface (Figure 5B and C, top).
No inhibition of LPS-induced DC activation (SYK-
independent) was observed (Figure 5C, bottom). In
whole blood from healthy donors, neutrophils were in-
duced to release reactive oxygen species (ROS) by stim-
ulation with opRBC to cross-link FcγR, or by E coli
to induce ROS via SYK-independent toll-like receptor
mechanisms. As shown in Figure 6A, opRBC-induced
ROS generation was completely abrogated by pretreat-
ing blood samples with 4 μM PRT062607. In replicate
experiments from different donors, PRT062607 inhib-
ited opRBC- but notE coli-inducedROS formation in a
concentration-dependent manner (Figure 6B). Impor-
tantly, the concentrations safely achieved in the human
SAD and MAD studies are sufficient to inhibit FcR-
mediated cellular responses in whole blood in vitro.
The percentage inhibition of SYK required for
efficacy in an in vivo model of inflammatory au-
toimmune disease was then estimated. We previously
demonstrated the exposure-efficacy relationship of
PRT062607 in the rat CIA model of inflammatory
arthritis.9 Supplemental Table S1A details the doses
tested, exposures achieved, and corresponding percent-
age inhibition of hind-paw inflammation. The mini-
mally effective exposure observed in this study was at
the 10 mg/kg dose, resulting in a Cav,ss of 0.72 μM. To
estimate the percentage of SYK inhibition in rats at this
exposure, we stimulated rat whole blood (immunized
with bovine collagen and presenting with hind-paw
inflammation scores of 1 to 2) with anti-BCR antibody
and measured phosphorylation of ERK Y204. Blood
from rats was tested independently and in triplicate on
3 separate days for BCR-mediated induction of pERK
Y204 and for responsiveness to increasing concentra-
tions of PRT062607 (Figure 7A, bar graph). Data
from 20 rats with inflammation scores of 1 to 2 were
pooled, and percentage inhibition was calculated to
generate a concentration-response profile (Figure 7A,
curve-fit). Average plasma concentrations achieved at
the 10 and 15 mg/kg dose levels in the rat CIA study
were extrapolated back to the percentage inhibition of
the BCR signaling pathway by PRT062607 and related
to the percentage inhibition of joint swelling in the
model. As indicated in the associated table, a concen-
tration of 0.72 μM corresponds to 40% inhibition of
the BCR/SYK signaling pathway and 55% inhibition
of hind-paw inflammation. Similarly, 1.34 μM corre-
sponds to a 57% inhibition of the BCR/SYK pathway
and to a 90% inhibition of hind-paw inflammation.
Figure 7B demonstrates the inability of PRT062607 to
inhibit PMA-induced pERK Y204 in rat blood, indi-
cating that the assay behavior compares well with the
human system. Percentage inhibition of the pathway at
Cmin,ss, Cmax,ss, andCav,ss at the 10mg/kg dose is detailed
in Supplemental Table S1B and ranges from 21% to
47% inhibition. To estimate the therapeutic exposures
of PRT062607 that may be required for efficacy in
patients with autoimmune diseases, we used the SAD
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Figure 5. Inhibition of immune-complex–mediated DC activation in vitro. (A) Differentiation of purified peripheral blood monocytes into imDCs via
IL4/GM-CSF is shown based on CD14 and CD1a expression. (B) Data represent DC activation as measured by surface expression of CD80/86 and
MCHII from replicate (n = 5) experiments. Pretreatment of cells with vehicle (Vh), anti-FcRIIa antibody (4.3) or an isotype control (mIgG), or various
concentrations of PRT062607 (μM) prior to stimulation with opsonized sheep red blood cells (opRBC) is indicated.Bars represent mean percentage of
vehicle plus standard deviation. (C) Representative CD80/86 expression data from opRBC (SYK-dependent)-stimulated cells (top histogram overlay)
and LPS (SYK-independent)-stimulated cells (bottom histogram overlay). Unstimulated cells are shown (No Stim); 1 μM PRT062607 was used as
indicated (+2607).
and MAD PK/PD relationships to extrapolate what
doses would be required to maintain SYK inhibition
levels above IC25, IC50, IC75, and IC90 (Table 4). Ef-
ficacy in the rat CIA model appears to be achievable
at approximately 50% inhibition of SYK. This level of
inhibition is maintained at Cmin,ss in humans with oral
doses ranging between 51 and 75 mg.
Discussion
Therapeutic targeting of the BCR signaling path-
way has been validated clinically for the treatment
of B-cell malignancies by 2 small-molecule kinase
inhibitors. Bruton’s tyrosine kinase (BTK) inhibitor
ibrutinib is indicated for the treatment of CLL, MCL,
and Waldenstro¨m’s macroglobulinemia.19–22 Similarly,
the PI3Kδ inhibitor idelalisib is approved for the
treatment of relapsed/refractory CLL in combination
with B-cell depletion by rituximab23 and as a single
agent for the treatment of relapsed/refractory follicu-
lar lymphoma.24 Although SYK is upstream of BTK
and PI3K on the BCR signaling pathway, the tissue
expressions of these 3 kinases are divergent, indicating
that each target does reflect its distinct biology. In spite
of the overall efficacy of the 2 agents (ibrutinib and
idelisib), recurring adverse events that appear to be
drug related have been identified for both. Neutropenia,
thrombocytopenia, diarrhea, and fatigue have emerged
as common safety concerns in treated patients. In
addition, increased rates of adverse events have been
observed in combination studies with idelisib and may
limit its potential to be used in conjunction with other
therapies. Unique kinase selectivity patterns of small-
molecule inhibitors may also offer the opportunity
to achieve distinct efficacy and safety profiles as a
consequence of targeting SYK, BTK, or PI3K.
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Figure 6. Inhibition of immune-complex–mediated NE oxidative burst in vitro. (A) Representative FACS plots demonstrating the effect of 4 μM
PRT062607 on immune complex (opRBC)-mediated neutrophil oxidative burst (y-axis). (B) Replicate experiments from 5 independent healthy blood
donors. Data represent mean neutrophil oxidative burst (ROS) as a percentage of vehicle control, plus standard deviation on the y-axis. PRT062607
concentration (μM) is presented on the x-axis. Black bars represent cells stimulated with opRBC (SYK-dependent), and gray bars represent cells
stimulated with E coli (non-SYK dependent).
Table 4. Concentrations Required to Maintain Various Levels of Target Inhibitiona
B-Cell Activation (CD69) Basophil Degranulation (CD63)
Conc (nM)
Dose AUC Cmax Dose AUC Cmax
Target CD63 CD69 (mg) (ng·h/mL) (ng/mL; nM) (mg) (ng·h/mL) (ng/mL; nM)
Maintain above IC25 110 152 41 1888 123; 313 33 1366 89; 226
Maintain above IC25 (upper 95% CI) 117 164 43 2049 134; 341 35 1486 97; 247
Maintain above IC50 205 324 71 4057 265; 674 51 2571 168; 427
Maintain above IC50 (upper 95% CI) 213 350 75 4378 286; 727 52 2651 173; 440
Maintain above IC75 381 687 121 8556 559; 1421 80 4780 312; 793
Maintain above IC75 (upper 95% CI) 395 778 133 9761 638; 1622 82 4941 323; 821
Maintain above IC90 709 1458 215 18,196 1188; 3019 124 8837 577; 1467
Maintain above IC90 (upper 95% CI) 753 1744 251 21,771 1422; 3614 129 9399 614; 1561
aConcentrations were extrapolated from PK/PD curve fit. Data were then used to estimate the dose (mg) required to maintain the calculated target
concentration. Cmax is shown in ng/mL and nM.
Thus far, SYK as a therapeutic target has not been
explored as thoroughly as BTK and PI3Kδ. Fosta-
matinib (a nonspecific SYK inhibitor) was originally
evaluated in patients with relapsed/refractory B-cell
malignancies, achieving partial responses in leukemias
and indolent and aggressive lymphomas,25 although a
follow-up phase 2 study in DLBCL was less promising
(overall response rate 3%).26 A series of phase 2 studies
were conducted in patients with RA; statistically signif-
icant improvements in ACR50 scores were achieved in
methotrexate-resistant patients27,28 but not in patients
who had failed prior therapy with TNF inhibitors.29
Unfortunately, phase 3 studies for fostamatinib in
RA did not meet their primary endpoints for clinical
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Figure 7. Inhibitory potency of PRT062607 against SYK activity in rat whole blood. (A) The bar graph represents replicate experiments (n = 3) from
a single rat whole-blood sample, showing the percentage of B cells that are positive for pERK Y204 following no stimulation (NS) or BCR stimulation
(anti-IgD) in the presence of the indicated concentrations of PRT062607.Data from 20 rats included as part of a CIA study were normalized to generate
percentage inhibition relative to vehicle control and plotted using a 3-parameter nonlinear curve fit to estimate the PRT062607 concentration-effect
relationship for SYK inhibition in rat whole blood. The table depicts the dose groups (10 and 15 mg/kg) that demonstrated statistically significant
efficacy in the rat CIA model, the Cav,ss achieved at each dose, the percentage inhibition of pERK Y204, and the percentage inhibition of hind-paw
inflammation. (B) The percentage of pERK Y204-positive B cells in rat whole blood following no stimulation (NS) or stimulation with PMA in the
presence of vehicle or 5 μM PRT062607 (n = 3).
benefit.30 Fostamatinib is currently being studied in
a phase 3 trial in immune thrombocytopenia31 (refer-
ence 31 and NCT02077192). Although it is difficult
to clearly interpret these data as clinical validation of
targeting SYK,32 the clinical results are suggestive and
consistent with the known etiology of these diseases.
In comparison to fostamatinib, PRT062607 is more
selective as an SYK inhibitor10,33 andmore potent when
tested head-to-head in whole blood BCR/SYK and
FcR1/SYK signaling and functional assays (data not
shown). Braselmann et al32 reported an IC50 of 1.06μM
with fostamatinib in the basotest assay following oral
administration to healthy volunteers; we report here
an IC50 of 0.2 μM and an IC90 of 0.7 μM in healthy
volunteers following the same route of dosing. Given
the specificity and potency differences, it is possible
that PRT062607 will elicit a different safety and effi-
cacy profile relative to fostamatinib. Of note, a dual
SYK/ZAP70 inhibitor (MK-8457) recently demon-
strated efficacy in patients with rheumatoid arthritis but
ultimately was not tolerated due to serious infections,
and the program was discontinued.34
Another SYK inhibitor in clinical development,
GS9973, appears to have a better selectivity profile
relative to fostamatinib.35 Kinases inhibited within a
10-fold potency range by this compound were
CSNK2A2, JAK2, SRC, and TNK1,36 with JAK2
and SRC being relevant to B-cell and tumor biology.
Efficacy in relapsed CLL patients was reported from
a phase 2 study, demonstrating that 94.5% of patients
achieved decreased adenopathy, with 61.5% of patients
having experienced a partial response. Duration of
response was greater than 6 months in the majority
of responding patients.37 It is difficult to assess the
exact level of SYK inhibition in this study, as only
changes in serum cytokines/chemokines were reported.
Estimating from reduction in serum levels of CCL3
and CCL4 (50% to 75%) as measures of BCR
signaling, it appears that the BCR pathway was not
completely suppressed since more potent inhibition
of these markers has been reported (>90%) by the
covalent BTKmodifier ibrutinib.38 Combining GS9973
with idelalisib in patients with B-cell malignancies was
not tolerated, and the study was discontinued.39 It is
unclear if the combination of these 2 agents was not
tolerated due to the combined SYK/PI3Kδ mechanism
or due to overlapping off-target toxicities of these
2 distinct kinase inhibitors derived from separate
chemistry scaffolds.
The PK profiles of PRT062607 following multiple-
dose administration were comparable to that follow-
ing single-dose administration, and plasma exposures
observed showed a greater than dose-proportional in-
crease as a function of dose in both SAD and MAD
studies. Caco-2-cell data suggest that PRT062607 is
highly effluxed by P-gp (data not shown), which may
be a contributing factor to the nonlinear increases in
exposure observed up to 100 mg in the SAD study and
up to 110 mg in the MAD study. Dose-proportional
increases, however, are seen beyond 200 mg in the SAD
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study, suggesting that the efflux mechanism of P-gp in
the gut may be saturated at these higher doses. Despite
the nonlinear increases in exposure, intersubject vari-
ability was found to be low to moderate, suggesting
that the PK behavior of PRT062607 is predictable.
In addition, PD response appeared to be directly re-
lated to PK response, and the pharmacologic activ-
ity of PRT062607 was maintained on repeat dosing.
There was little contribution via renal excretion to the
overall elimination of PRT062607. Renal clearance of
PRT062607 was determined to be nearly equivalent to
the glomerular filtration rate when the protein binding
of PRT062607 in human plasma (93.5%) is taken into
account. Low renal clearance offers a benefit when
this drug is administered to elderly patient populations,
such as those with rheumatoid arthritis, where compro-
mised renal function is prevalent.
One consistent observation made with PRT062607
both preclinically and following oral dosing in humans
is a potent inhibition of FcR1 signaling. We do
not have a clear mechanistic understanding of this
observation, but the combined SAD/MADhuman data
indicate an approximately 2-fold increase in potency of
suppressing FcR1-mediated basophil degranulation
relative to BCR-mediated signaling or activation. Based
on the clinical studies, we have estimated that inhibition
of peripheral blood basophil degranulation by 50% can
be achieved at a concentration of 0.2 μM, which
would be maintained at a dose of 51 mg, and by 90%
at around 0.7 μM, which would require a projected
dose of 130 mg. Preclinical models support targeting
SYK for allergic disease. Wex et al40 demonstrated
in a conditional knockout model that SYK was crit-
ical for the generation of mast cell–mediated aller-
gic and inflammatory responses. Aerosolized antisense
oligonucleotides targeting SYK effectively blocked
inflammatory responses in a rat model of allergen-
induced asthma.41 Independent chemical scaffolds that
target SYK have demonstrated efficacy in animal
models of allergic disease (reviewed by Pamuk and
Tsokos),42 and intranasal delivery of the SYK inhibitor
R112 improved clinical symptoms of seasonal allergic
rhinitis.43 The data suggest that PRT062607 could be
utilized as a tool to explore the full range of FcR1
signaling inhibition for therapy in type I hypersensi-
tivity allergic reactions such as allergic asthma, atopic
dermatitis, or even severe life-threatening food or drug
allergies.
As reported here, an average of 40% inhibition of
rat peripheral blood BCR signaling was associated
with resolution of inflammation and joint destruction
in the animal model of RA. Most likely, this was
a function of a mixed reaction of suppressing BCR
signaling and autoantibody production as well as in-
hibiting FcγR-mediated activation of effector myeloid
cells. The combined effect of targetingmultiple relevant
immunological mechanisms may have contributed to
the observation that low-level inhibition of a single
pathway was sufficient for disease resolution. Exper-
imentally, SYK is required for FcγR-mediated acti-
vation of macrophages and neutrophils,6,17 and SYK
expression in neutrophils is required for the develop-
ment of inflammation and disease symptoms in the
K/BxN serum transfer model of arthritis.44 Consis-
tently, reconstitution of the hematopoietic system of
irradiated mice with SYK knockout fetal liver cells
protects against autoantibody-mediated arthritis.45 To
confirm the requirement of SYK in established mature
immune cells for arthritis development, Ozaki et
al46 have demonstrated that conditional SYK knock-
out mice were completely protected from collagen
antibody–induced arthritis. The protection from in-
flammation was associated with defective signaling
and functional responses following FcγR ligation in
macrophages and neutrophils.
In conclusion, SYK remains an attractive target for
certain autoimmune diseases and B-cell malignancies,
yet its potential has not been fully explored. Animal
models predict that complete suppression of SYK
activity may not be needed to elicit clinical response
by PRT062607. Dose-ranging clinical studies will be
required with PRT062607 to determine the level of
pathway suppression required for efficacy. Results from
the healthy normal volunteer studies suggest that the
full range of SYK inhibition by PRT062607 can be
safely explored in humans and can enable identification
of a pharmacological profile customized to individual
target patient populations.
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